Research Explainer
What does GLP-1 adoption mean for food brands and retailers?
Observational research on U.S. household purchases suggests that after someone in a household starts a GLP-1 medicine, that household spends somewhat less on groceries on average, with the largest drops in calorie-dense snack categories. For food companies, that is a useful signal about changing demand. It is not a forecast for any single brand, and it does not measure what people actually ate.
What kind of evidence this is
The research is “The No-Hunger Games: How GLP-1 Medication Adoption Is Changing Consumer Food Demand,” by Sylvia Hristakeva, Jūra Liaukonytė and Leo Feler, published in the Journal of Marketing Research in December 2025.[1]It is not a clinical trial. The researchers linked survey answers about GLP-1 use to purchase records from a panel of about 150,000 U.S. households. Their main analysis followed 2,602 households that adopted a GLP-1 medicine, each compared with a similar household that did not, matched on demographics, diabetes status and earlier shopping patterns.[2] Most households in the wider panel were not GLP-1 users.
What the study found
All figures below are average changes in household spending, from the journal abstract:[1]• Groceries: households reduced grocery spending by 5.3% on average within six months of adoption. This is a household-level average, not a 5.3% fall in national grocery sales.• Higher-income households: reduced grocery spending by 8.2%.• Savory snacks: spending fell 10.1%, the largest decline among categories highlighted; most categories declined.• Limited-service restaurants: spending at fast-food chains, coffee shops and other limited-service restaurants fell 8.0%. This does not cover all restaurant spending.• Over time: the changes persisted through the first year, though they became smaller after six months.These are spending changes, not measurements of calorie intake.Among the 40 largest food categories examined, yogurt was the only category with a statistically significant positive spending estimate.[2] Fresh fruit, nutrition bars and meat snacks also had positive estimates, but those were not statistically significant.[2]
When households stop
Approximately one-third of adopting households in the study sample discontinued during the observation period.[2] After discontinuing, their grocery spending moved back toward earlier levels, and their baskets shifted slightly toward less healthy categories compared with their original baseline.[1][3] That is a pattern in this sample, not a guaranteed outcome.For businesses, the takeaway is that GLP-1 households are not a fixed customer group: people start, continue and stop. Our explainer on stopping GLP-1 medicines covers the clinical side.
What the study cannot tell you
Household purchases are not individual consumption. Treatment was not randomly assigned, and other lifestyle changes may contribute. The findings do not predict every customer’s behavior.[2]
Questions for businesses (interpretation, not findings)
The study measures category spending. What follows are questions it raises, not outcomes it proves:• Portions: if households buy less, do portion size and value per serving matter more?• Product development: what does a product need to offer when appetite is smaller? There is no requirement that every brand make a “GLP-1 product.” See what “GLP-1 friendly” means on a label.• Assortment: how exposed is a range to the categories that declined? A positive estimate for yogurt in one study is not a guaranteed growth opportunity.• Understanding customers: users differ by age, income and reason for treatment. In the study, people using GLP-1s for weight loss tended to be younger and higher-income than those using them for diabetes.[2] Not every user shops alike.
Where the conversation continues
The GLP-1 Summit + Expo takes place at The Conference Center at RidgeGate, Denver, Colorado, October 7–9, 2027, with Day 1 — Industry Day on Friday, October 8 covering consumer behavior, market developments and the businesses responding to GLP-1 adoption. The program is in development. Explore Industry Day.
Disclosure: The publication lists co-author Leo Feler as Chief Economist at Numerator, which supplied the purchase data.[1]
This page is for general education and event programming. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.
Sources
- [1]The No-Hunger Games: How GLP-1 Medication Adoption Is Changing Consumer Food Demand (abstract)Journal of Marketing Research, December 2025Read the source (opens in a new tab)
- [2]How are weight-loss drugs changing our food shopping? (authors’ explanation)Economics ObservatoryRead the source (opens in a new tab)
- [3]Ozempic is changing the foods Americans buyCornell Chronicle, December 19, 2025Read the source (opens in a new tab)
